The live NEES catalogue title describes Disolvidase as hyaluronidase 1,500 I.U., but Dermaqual's current product page instead describes a topical cosmetic enzymatic complex and does not list hyaluronidase or a 1,500 I.U. strength.

This discrepancy is clinically material: clinics must identify the exact supplied product from its current label and must not treat topical Disolvidase as injectable hyaluronidase or as emergency management for a filler complication.

Catalogue visual: Disolvidase | Hyaluronidase 1,500 I.U. Filler Corrective from the NEES Medical product catalogue. Packaging appearance alone does not establish authenticity; verify the supplied batch, expiry, seals and traceability documents.

What it is

Dermaqual currently describes Disolvidase as a professional topical cosmetic preparation intended to improve the appearance of superficial irregularities after hyaluronic acid aesthetic treatment. It explicitly states that the action is cosmetic and superficial, that the product does not replace injectable treatment, and that it is not indicated for medical complications. No ingredient named hyaluronidase or potency of 1,500 I.U. appears on the current public page. The NEES title therefore requires verification and correction against the physical stock and current manufacturer documentation before publication or sale.

Market position and alternatives

Topical cosmetic smoothing, elective correction with licensed hyaluronidase and urgent vascular-occlusion management are different categories and must not be conflated.

Potential advantages

• The current manufacturer page clearly limits the product to topical professional cosmetic use.
• The five-vial presentation provides traceable individual containers when supplied in the original sealed carton.
• The product may offer a conservative surface-care option when a practitioner has excluded a medical complication.
• The explicit manufacturer warning helps clinics separate cosmetic irregularity from urgent adverse-event management.

Limitations and buying considerations

• The catalogue's hyaluronidase 1,500 I.U. title conflicts with the current manufacturer information and should not be relied on.
• The manufacturer does not publicly identify the composition or enzyme concentration of the current cosmetic complex.
• No product-specific controlled clinical evidence was found for correction of filler irregularities.
• Pain, blanching, livedoid change, visual symptoms, neurologic symptoms or worsening swelling after filler require urgent medical assessment.

Quality and authenticity checklist

• Pause procurement if the stock label, NEES title and Dermaqual page describe different ingredients, strengths or routes.
• Obtain the current manufacturer instructions and verify whether the physical lot is topical cosmetic Disolvidase or a different regulated medicine.
• Check the carton and all vials for matching lot, expiry and tamper evidence.
• Do not buy unlabelled powder, loose vials or products presented as injectable solely on a reseller's description.

Price and availability in Pakistan

The current Disolvidase price in Pakistan is available by quotation from NEES Medical; no numeric PKR price is published. NEES should resolve the title-versus-manufacturer discrepancy before quoting, and the quotation should identify the exact route, presentation and current labelled composition.

Sources and further reading

• Dermaqual — Disolvidase Current Product Listing
• Guideline for the Safe Use of Hyaluronidase in Aesthetic Medicine
• CMAC Guideline: Management of Hyaluronic Acid Filler-induced Vascular Occlusion

View the Disolvidase | Hyaluronidase 1,500 I.U. Filler Corrective catalogue page or request current pricing and availability.